Low Dose Naltrexone (LDN) has been reported anecdotally to reduce the symptoms of Fibromyalgia, a Chronic Multisystem Illness. The drug may work by regulating natural pain-reducing systems. In this study, we will administer both LDN and placebo to a small group of individuals with Fibromyalgia and Gulf War Syndrome, both Chronic Multisymptom Illnesses, to assess the drug's efficacy in treating the condition.
Stanford is currently not accepting patients for this trial.
Collaborator: American Fibromyalgia Syndrome Association
Currently suffering from moderate to severe Fibromyalgia or symptoms of Gulf War Syndrome
Age 18-65. Not taking any opioid analgesic Not pregnant or planning to become pregnant.
Any known allergy to naltrexone or naloxone. Actual or planned pregnancy.
18 Years - 65 Years